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Thioredoxin-interacting protein (TXNIP) has been widely recognized as a
tumor suppressor in various cancers, including liver, breast, and thyroid
cancers. Although TXNIP is epigenetically silenced in acute myeloid leuke-
mia (AML) cells, as in many cancer cells, its role in leukemogenesis
remains elusive. Mixed-lineage leukemia (MLL) gene rearrangements in
AML are associated with poor prognosis, and the development of a new
treatment method is eagerly anticipated. In this study, we first reveal that
lower expression of TXNIP is correlated with shortened overall survival
periods in AML patients. Moreover, we demonstrated that TXNIP overex-
pression significantly suppresses proliferation in AML cells harboring MLL
fusion genes. TXNIP promotes autophagy by increasing expression of the
autophagy protein, Beclin 1, and lipidation of LC3B. We also show that
TXNIP overexpression combined with ABT263, a potent inhibitor of Bcl-2
and Bcl-xL, is highly effective at inducing cell death in MLL-rearranged
(MLL-r) AML cells. In summary, this study provides insights into the
molecular mechanism of TXNIP-mediated tumor suppression and further-
more underscores the potential of TXNIP as a promising therapeutic target
for MLL-r AML.
Acute myeloid leukemia (AML) is a malignant disease,
in which immature blood cells aberrantly expand in the
bone marrow and lose their normal hematopoietic func-
tion. Although the treatment outcome of AML is
improving, the 5-year recurrence-free survival rate of
adult AML is about 40% [1]. In addition, AML thera-
peutic sensitivity and prognosis are greatly different
depending on the subtypes of leukemia and the underly-
ing genetic abnormality. The standard treatment for
AML is chemotherapy with a combination of cytara-
bine and anthracycline; however, it often results in poor
prognosis due to the acquired resistance [2]. Mixed-lin-
eage leukemia (MLL)-rearranged (MLL-r) leukemia is
characterized by chromosomal translocations of MLL
gene, located at 11q23, to form fusion proteins with
various partner proteins [3]. Rearrangements of MLL
gene are found in 5–10% of all acute leukemia and in up
to 85% of secondary leukemia after treatment with
DNA topoisomerase II inhibitors, often accompanied
with unfavorable prognosis [2,4]. Therefore, it is eagerly
desired to identify the underlying factors of malignancy
and to develop a new therapeutic strategy for refractory
AML, such as MLL-r AML.
We identified thioredoxin-binding protein 2, also called
thioredoxin-interacting protein (TXNIP) or vitamin D3
upregulated protein 1 (VDUP-1), as a negative regulator
of the key antioxidant system thioredoxin (TRX) [5].
TXNIP plays a role in a wide variety of physiological
Abbreviations
AML, acute myeloid leukemia; MLL, mixed-lineage leukemia; TXNIP, thioredoxin-interacting protein; VDUP-1, vitamin D3 upregulated protein 1.
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processes [6] including glucose metabolism [7–9], lipid
metabolism [10,11], and immune and inflammatory
responses [12–14]. We previously reported that TXNIP
knockout mice were predisposed to death under fasting
conditions due to hyperlipidemia, hypoglycemia, bleed-
ing tendency, and hepato-renal insufficiency [11]. These
results show that TXNIP is essential in the fasting
response. Furthermore, TXNIP plays important roles in
regulating cell death, growth, and differentiations. A
number of studies have shown that TXNIP expression is
decreased in various cancer cells. Loss of TXNIP in mice
promoted hepatocarcinogenesis [15]. Disruption of
TXNIP is important for the development of breast and
thyroid cancers [16,17]. Downregulation of TXNIP pro-
motes tumor proliferation, migration, and metastasis by
remodeling of extracellular matrix [18]. In adult HTLV-1
T-cell leukemia (ATL), the loss of TXNIP expression is
involved in T-cell leukemia progression [19]. Decreased
expression of TXNIP has also been reported in AML
cells. TXNIP is silenced in AML cells by two epigenetic
regulators, histone deacetylation and H3K27me [20].
These studies suggest that TXNIP is involved in AML
development, but the precise mechanism is unknown.
Autophagy is a self-digesting mechanism, in which
cytoplasmic components including organelles are
sequestered within double-layer membrane that delivers
their contents to lysosomes for degradation [21,22].
Although autophagy is conspicuously activated through
starvation, it is induced at low levels under eutrophic
conditions to maintain cellular homeostasis [23,24]. The
role of autophagy in cancer is complicated because of
its dual functions as a tumor suppressor and promoter.
Deficiency of autophagy in mice causes multiple liver
tumors [25,26]. However, autophagy accelerates the
tumorigenesis of K-RasG12D-driven lung cancer [27,28].
These studies suggest that whether autophagy works
for cancer suppression or promotion depends on the
type of tissue, genetic background, and the stage of
tumor development. TXNIP is reported to promote
autophagy by interacting with autophagy regulator
REDD1 [29,30], suggesting that TXNIP may trigger
autophagic death in AML cells. In spite of these find-
ings, the precise molecular mechanisms behind TXNIP
tumor suppressor activity and the functional associa-
tion between TXNIP and autophagy have remained
entirely elusive.
In this study, we compared the prognosis of AML
subtypes between TXNIP low and high groups and
the expression levels of TXNIP. Besides, we examined
the effect of TXNIP overexpression on the cell growth
of MLL-r AML cells. These findings propose a




MLL-r AML-derived MOLM-13 and MV4-11 cells were
purchased from Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (DSMZ, Braunschweig, Germany),
and American Type Culture Collection (ATCC, Manassas,
VA, USA), respectively. These MLL-r AML cell lines were
cultured in Roswell Park Memorial Institute 1640 medium
containing 10% heat-inactivated FBS and 1% penicillin–
streptomycin (PS) under 5% CO2 and 95% air at 37 °C.
Embryonic kidney HEK293T cells were obtained from Japa-
nese Collection of Research Bioresources (JCRB, Ibaraki,
Osaka, Japan). HEK293T cells were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10%
FBS and 1% PS under 5% CO2 and 95% air at 37 °C.
Expression plasmids
Human TXNIP cDNA was amplified by PCR and then
inserted into CSIV-TRE-Ubc-KT expression vector
(RIKEN, BRC, Tsukuba, Ibaraki, Japan). All the PCR
products were verified through DNA sequencing.
Production and transduction of lentivirus
For the production of lentivirus, HEK293T cells were tran-
siently cotransfected with packaging and envelope plasmids,
such as psPAX2 and pMD2.G, by polyethylenimine
(Sigma-Aldrich, St. Louis, MO, USA). Forty-eight hours
after transfection, viral supernatants were collected and
immediately used for infection, and the successfully trans-
duced cells were then sorted using flow cytometer Aria III
(BD Biosciences, Franklin Lakes, NJ, USA) based on
immunofluorescence (Kusabira-Orange).
Cell proliferation
To assess cell proliferation, 5 9 104 cells of MOLM-13 and
MV4-11 cells were seeded in 6-well plates. For tetracycline-
inducible gene, doxycycline was added to the culture at a
final concentration of 3 µM. Trypan blue dye exclusion
assays were performed every other day.
Immunoblotting
Cells were washed in PBS and then lysed in Triton X-100
lysis buffer (20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1%
Triton X-100, protease inhibitor EDTA free). After cen-
trifugation, the protein content of the supernatants was
measured using DC Protein Assay (Bio-Rad Laboratories).
Equal amounts of whole-cell lysates were separated by
SDS/PAGE and then electrotransferred onto polyvinylidene
difluoride membranes. Membranes were probed with the
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following primary antibodies: anti-VDUP-1 (Invitrogen, 40-
3700, Carisbad, CA, USA), anti-GAPDH (Santa Cruz
Biotechnology, Inc., 0411, Dallas, TX, USA), anti-LC3B
(Cell Signaling Technology, #3738, Danvers, Essex, MA,
USA), and anti-BECN1 (Cell Signaling Technology,













































Fig. 1. Lower expression level of TXNIP is associated with poor prognosis. (A) Overall survival of relapsed and refractory AML patients with
higher or lower expression levels of TXNIP (GSE5122, high n = 46, low n = 12). P value by log-rank (Mantel–Cox) test. (B) Expression levels
of TXNIP in indicated primary AML cells (GSE6891). AML cells are compared to their nearest normal counterpart. Data are expressed as
















































Fig. 2. Doxycycline-induced TXNIP
suppresses proliferation of MLL-r AML
cells. (A) Expression of TXNIP in
doxycycline (dox)-on-dependent TXNIP-
overexpressed MOLM-13 and MV4-11
cells. Cells were treated with or without
3 lM doxycycline. Seventy-two hours after
treatment, cell lysates were prepared and
analyzed by immunoblotting with the
indicated antibodies. GAPDH was used as
loading control. Images are representative
images of three reproducible independent
results. (B) Growth curves of dox-on-
dependent TXNIP-overexpressed MOLM-
13 and MV4-11 cells treated with or
without doxycycline (n = 3). Data are
expressed as the mean  SEM values.
**P < 0.01, ***P < 0.001, by 2-tailed
Student’s t-test.
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anti-rabbit IgG and anti-mouse IgG (GE Healthcare Life
Sciences, Marlborough, MA, USA) were used. Blots were
visualized using Chemi-Lumi One Super (Nacalai Tesque)
and ChemiDoc XRS + Imager (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s
recommendations.
Transmission Electron Microscope (TEM)
Acute myeloid leukemia cells were collected by centrifu-
gation, fixed in 0.1 M phosphate buffer containing 4%
paraformaldehyde/2% glutaraldehyde at 4 °C, washed in
isotonic phosphate-buffered sucrose, and then refixed in
phosphate-buffered 1% OsO4. Following dehydration in a
graded series of EtOH washes, the cells were embedded
in LUVEAK-812 (Nacalai Tesque). Thin sections (70–
90 nm thick) were cut on EM UC6 Ultramicrotome using
a diamond knife (Leica, Heidelberg, Germany), stained
with uranyl acetate and lead citrate, and then observed
under H-7650 electron microscope (Hitachi, Tokyo,
Japan).
Reagents
ABT263 was purchased from Cayman Chemical (Ann
Arbor, MI, USA).
Cell cycle and apoptosis assay
For cell cycle analysis, cells were fixed in 100% EtOH fol-
lowed by incubation with PBS containing 100 µgmL1 of
RNase A. Cells were then stained with 50 µgmL1 propid-
ium iodide and subjected to flow cytometric analysis. For
apoptosis assay, apoptotic cells were detected by annexin
V–FITC conjugate (Invitrogen). In brief, ~ 2 9 105 cells
were washed in PBS, suspended in annexin-binding buffer,
and then mixed with 5 µL of annexin V. The reaction mix-
tures were incubated for 30 min. After incubation, cells
were diluted, stained with 5 µgmL1 of DAPI (Invitrogen)
or 5 µgmL1 of Hoechst 33342 (Invitrogen), and processed
for flow cytometric analysis.
IC50 evaluation
For cell survival assay, cells were seeded at a density of
1 9 105 cells per mL. ABT263 was added to the culture
medium, and cells were incubated for 48 h. Cell viability
was then assessed using Cell Count Reagent CellTiter 96
AQueous One Solution Cell Proliferation Assay System
(Promega, Madison, WI, USA) and VersaMax microplate
reader (Molecular Devices, San Jose, CA, USA) according
to manufacturer’s instructions. Percent inhibition curves
were drawn, and IC50 of ABT263 was calculated based on
the median-effect method [31].
Statistics
Statistically significant differences between control and
experimental groups were assessed using 2-tailed unpaired
Student’s t-test and showed if the P value was < 0.05. Equal-
ity of variances in two populations was calculated with
F-test. The results were represented as the average  SEM
values obtained from three independent experiments.
PrognoScan software (http://gibk21.bse.kyutech.ac.jp/
PrognoScan/index.html) was utilized for data extraction
and calculation of minimal P value [32]. Survival between
the indicated groups was compared using log-rank test.
Results
TXNIP overexpression exerts antileukemic effect
We first analyzed the clinical datasets, and we revealed
that lower TXNIP expression was associated with poor
prognosis in patients with refractory AML and
relapsed AML (Fig. 1A). To investigate whether
TXNIP expression is different among AML sub-
groups, we further analyzed clinical datasets and found
that TXNIP expression was most decreased in MLL-r
AML cells (Fig. 1B). We thus decided to perform
functional analysis of TXNIP using MLL-fused AML
cell lines, MOLM-13 and MV4-11. Both cell lines were
obtained from MLL-r AML patients with high-risk
factor FLT-3 ITD. To investigate TXNIP overexpres-
sion-mediated cellular responses, we constructed tetra-
cycline-inducible TXNIP expression vector and
lentivirally transduced it into MOLM-13 and MV4-11
(Fig. 2A). As shown in Fig. 2B, TXNIP overexpres-
sion significantly suppressed MOLM-13 and MV4-11
cell proliferation. These data indicate that decreased
expression of TXNIP confers leukemogenesis.
To investigate the mechanism of growth suppression
by TXNIP, we first performed cell cycle analysis and
apoptosis assay. TXNIP overexpression changed nei-
ther the distribution of cell cycle stages nor the num-
ber of apoptotic cells (Fig. 3A,B). Meanwhile, TXNIP
overexpression notably increased the number of
annexin V-negative/DAPI-positive cells (Fig. 3B).
These data suggest that TXNIP enhanced the perme-
ability of plasma membrane or promoted nucleus swel-
ling. To analyze this, we performed nuclear staining
with Hoechst 33342. Hoechst 33342 is able to pene-
trate the plasma membrane of live cells, while DAPI is
not. Intriguingly, TXNIP overexpression did not affect
the number of Hoechst 33342-positive cells (Fig. 3C).
These results suggest that nuclear size did not change,
and the permeability of cell membrane was enhanced
by increased expression of TXNIP.
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Growth inhibition caused by TXNIP
overexpression involves autophagy in MLL-r AML
cells
Since TXNIP is a critical regulator of metabolism and
fasting response, we assumed that TXNIP inhibits
MLL-r AML cell growth by inducing autophagy.
Immunoblotting analysis revealed that TXNIP overex-
pression markedly upregulates Beclin 1 and LC3B-II,
both of which are the biomarkers of autophagy
(Fig. 4A. A classic autophagy detection tool, TEM, also
showed the formation of autophagosome in TXNIP-
overexpressed MOLM-13 and MV4-11 (Fig. 4B). These
results indicate that TXNIP does not promote apoptosis
but autophagy. It has been reported that Beclin 1 inhi-
bits apoptotic signaling in AML cells by enhancing Bcl-
xL binding to Beclin 1 and reducing Bad-Bcl-xL com-
plex that promotes apoptosis [33]. Therefore, we tested
the effect of ABT263, a BH3 mimetic that targets Bcl-2
and Bcl-xL proteins [34], on TXNIP-overexpressed
MOLM-13 and MV4-11 cells. Notably, TXNIP overex-
pression in MLL-r AML cells enhanced sensitivity to
ABT263 (Fig. 5A,B). Therefore, our present study
shows that TXNIP causes growth arrest and positively
regulates autophagy in MLL-r AML cell lines, enhanc-
ing the effect of ABT263.
Discussion
Recent studies have revealed that TXNIP is silenced in
a wide range of cancer cells. TXNIP is downregulated
in bladder cancer based on the grade and stage [35].
Moreover, low TXNIP expression is reported as a
potent prognostic biomarker for gastric cancer recur-
rence [36]. These findings suggest that depletion of
TXNIP endows cancer cells with survival and growth
advantages. Thus, we assumed that TXNIP expression
might be decreased in AML with high-grade malig-
nancy. Prognostic analysis using clinical datasets
revealed that lower TXNIP expression is associated
with poor prognosis in refractory AML and relapsed
AML. Zhou et al. [20] described that TXNIP is epige-
netically repressed in AML cells. However, it has been
unknown whether the expression of TXNIP varies
among the subtypes of AML. We analyzed clinical
datasets and examined the relationship between
TXNIP expression and common chromosome abnor-
malities in AML. Against our expectations, TXNIP
expression was increased in AML with t (8; 21) and t
(15; 17) (Fig. 1B). However, TXNIP was suppressed in
AML with inversion 16 (inv (16)) and MLL rearrange-
ments (Fig. 1B). MLL-r leukemia, in which TXNIP
expression is most decreased, is caused by transloca-
tion of 11q23 with more than 30 different chromoso-
mal sites resulting in MLL fusion genes. MLL
regulates histone methylation and is involved in chro-
mosome remodeling [2]. Changes in histone methyla-
tion patterns due to MLL fusion protein may
contribute to the reduction of TXNIP in AML cells.
Inhibition of glucose uptake and activation of apop-
tosis via reactive oxygen species have been reported as
the main mechanisms of tumor suppression by
TXNIP; however, the unified molecular mechanism
has not been clarified. In this study, we performed
TXNIP overexpression experiments in two AML cell
lines with MLL abnormalities. MOLM-13 carries
t(9;11) and expresses MLL-AF9, which is the most
common MLL rearrangements, generally accompanied
by intermediate risk [37–39]. MV4-11 carries t(4;11)
and expresses MLL-AF4, which shows poor prognosis
[39]. Interestingly, TXNIP suppressed cell prolifera-
tion, but exerted no influence on cell cycle or apopto-
sis (Fig. 3A,B). Based on these results, we considered
that the antileukemic effect of TXNIP involves the
mechanisms other than cell cycle arrest and apoptosis.
annexin V/DAPI staining revealed that TXNIP over-
expression promotes plasma membrane permeabiliza-
tion (Fig. 3C), which might weaken cells and confers
disadvantages for their survival. Further, we suspected
autophagy because TXNIP is a crucial regulator of
metabolism and response to fasting. We found that
TXNIP promotes autophagy by increasing Beclin 1 at
the protein level. The most common autophagy indu-
cer is rapamycin, an mTOR inhibitor, but it has clini-
cal risks of adverse side effects [40]. Furthermore, it
Fig. 3. TXNIP regulates plasma membrane permeabilization. (A) TXNIP overexpression does not change the distribution of cell cycle stages.
Dox-on-dependent TXNIP-overexpressed MOLM-13 and MV4-11 cells were treated with or without 3 lM doxycycline. Cells were harvested
and analyzed by flow cytometry 72 h after treatment (n = 3). (B) TXNIP overexpression does not affect the number of annexin V-positive
cells but affects the number of DAPI-positive cells. Dox-on-dependent TXNIP-overexpressed MOLM-13 and MV4-11 cells were treated as in
A, and the number of cells stained with indicated fluorescent probes was scored by flow cytometric analysis (n = 3). (C) TXNIP
overexpression does not influence the number of Hoechst 33342-positive cells. Dox-on-dependent TXNIP-overexpressed MOLM-13 and
MV4-11 cells were treated as in A, and the number of cells stained with indicated fluorescent probes was scored by flow cytometric
analysis (n = 1). Data are expressed as mean  SEM values. *P < 0.05, **P < 0.01, N.S., not significant, by 2-tailed Student’s t-test.
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has been reported that it does not induce autophagy
in AML cells as in other cancer cells [41], which sug-
gests that autophagy induction in AML cells may
involve different mechanisms from solid tumors.
Autophagy suppresses and promotes apoptosis
depending on the cellular circumstances [42]. We
showed that TXNIP overexpression increases sensitiv-
ity of leukemia cells to the Bcl-2 and Bcl-xL inhibitor,
ABT263, by promoting apoptosis induction (Fig. 5A,
B). Meanwhile, TXNIP did not augment the effect of
Bcl-2 selective inhibitor, ABT199 (data not shown).
Considering these data and a previous study, which
described that Beclin 1 suppresses apoptosis by
interacting with Bcl-xL [33], it is possible that inhibi-
tion of Bcl-xL is essential for the induction of cell
death in TXNIP-overexpressed MLL-r AML cells.
Although further studies are required to verify interac-
tion between TXNIP and Bcl-2 family, our findings
indicated that TXNIP overexpression-induced autop-
hagy increases sensitivity to ABT263.
In conclusion, we demonstrated that TXNIP inhibits
leukemogenesis possibly via induction of autophagy,
and a combination treatment with Bcl-xL inhibitors is
highly effective in promoting apoptosis. These findings
have the potential to establish a promising therapy



































































Fig. 5. TXNIP enhances the effect of
ABT263. (A) IC50 value of ABT263 in dox-
on-dependent TXNIP-overexpressed
MOLM-13 and MV4-11 cells treated with
or without doxycycline (n = 3). Dox-on-
dependent TXNIP-overexpressed MOLM-
13 and MV4-11 cells were treated
simultaneously with 3 lM doxycycline and
various concentrations of ABT263. Forty-
eight hours after treatment, IC50 values
were calculated. (B) TXNIP enhanced ABT-
263-induced apoptosis. Dox-on-dependent
TXNIP-overexpressed MOLM-13 and MV4-
11 cells were treated simultaneously with
3 lM doxycycline and 300 nM ABT263.
Forty-eight hours after treatment, the
number of cells stained with annexin V
was scored by flow cytometric analysis
(n = 3). Data are expressed as
mean  SEM values. **P < 0.01,
***P < 0.001, by 2-tailed Student’s t-test.
Fig. 4. TXNIP induces autophagy in MLL-r AML cells. (A) Immunoblot analysis showing increased lipidated LC3B (LC3B-II, bottom band) and
Beclin 1 in TXNIP-overexpressed MOLM-13 and MV4-11 cells. Dox-on-dependent TXNIP-overexpressed MOLM-13 and MV4-11 cells were
treated with or without 3 lM doxycycline. Cell lysates were prepared and analyzed by immunoblotting with the indicated antibodies 72 h
after treatment (n = 3). GAPDH was used as loading control. (B) TEM analysis of TXNIP-overexpressed MOLM-13 and MV4-11 cells. Dox-
on-dependent TXNIP-overexpressed MOLM-13 and MV4-11 cells were treated with or without 3 lM doxycycline. Seventy-two hours after
treatment, cells were harvested and examined by TEM. Representative magnified images are shown in the right. The black arrows in the
image indicate typical double-layer membrane autophagosomes. Scale bars, 2 or 0.5 lm. Images are representative images of two
reproducible independent results. Data are expressed as mean  SEM values. *P < 0.05, **P < 0.01, by 2-tailed Student’s t-test.
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